In the ongoing Omicron era, a new COVID-19 antibody could renew optimism for urgently required SARS-CoV-2 monoclonal ...

These antibody therapies against ccRCC are developed as both recombinant and synthetic DNA (synDNA) medicines.” The ...

Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new ...

Posters presented at ASCO 2024 found positive responses in the prediction of tumor types and prognostic outcomes in patients ...

The production of antibodies, essential for protecting our body against infections, is very well regulated through the action ...

A n investigational monoclonal antibody appeared to have therapeutic benefits among kidney transplant patients with antibody-mediated rejection, a randomized phase II trial showed.

Antibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating number of U.S. Food and Drug Administration (FDA) approvals and rapidly growing market size, as ...

J&J will pick up Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab Therapeutics, for $1.25 billion to acquire ...

AbbVie’s antibody-drug conjugate Elahere, developed by ImmunoGen, elicited a nearly 52% objective response rate in heavily ...

Tumor cells often hijack normal physiological processes to support their growth, exploiting proteins that are in charge of ...

In part 1 of our 3-part series, antibody-drug conjugates are revolutionizing oncology, targeting cancer cells precisely.